Sistema de Salut de Catalunya
Institut Català de la Salut
[Westphalen CB] Comprehensive Cancer Center Munich & Department of Medicine III, University Hospital, LMU Munich, Munich. German Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Boscolo Bielo L] Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. [Aftimos P] Clinical Trials Conduct Unit, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium. [Beltran H] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. Harvard Medical School, Boston, USA. [Benary M] Charité Comprehensive Cancer Center, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. Core Unit Bioinformatics, Berlin Institute of Health at Charité–Universitätsmedizin Berlin, Berlin, Germany. German Cancer Consortium (DKTK), partner site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Chakravarty D] Kravis Center for Molecular Oncology, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. [Dienstmann R] Vall d’Hebron Institute of Oncology (VHIO), Hospital Vall d’Hebron, Barcelona, Spain. University of Vic – Central University of Catalonia, Vic, Spain. Oncoclínicas&Co, São Paulo, Brazil. [Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Hospital Vall d’Hebron, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-10-16T06:17:59Z
2025-10-16T06:17:59Z
2025-06
Molecular tumour boards; Precision medicine; Precision oncology
Juntas de tumores moleculares; Medicina de precisión; Oncología de precisión
Juntes de tumors moleculars; Medicina de precisió; Oncologia de precisió
Background With an increased uptake of genomic profiling in clinical practice and the evolving complexity of diagnostic modalities, vast amounts of complex data need to be properly interpreted and integrated into an individualised care plan. To address these challenges, molecular tumour boards (MTBs) have been widely established. As of today, no international recommendations regulating the composition and workflows of MTBs have been defined. Methods ESMO’s Precision Oncology Working Group (POWG) established an international expert panel in precision oncology and defined core areas of interest. After several consultations and through an expert consensus process, the group reached a consensus level for each recommendation. Results The group defined five components in the MTB process that are critical to its function and clinical use: (i) the primary task of MTBs consists in providing genomic-informed clinical recommendations, particularly for cases exhibiting complex genomic alterations; (ii) to achieve this, MTBs should encompass interdisciplinary expertise, with key roles for oncologists with genomic expertise, pathologists with molecular training and clinical geneticists; (iii) MTBs’ recommendations should be documented in a structured report that includes genomic-informed treatment strategies, management plans for potential tumour-detected germline alterations and guidance for additional genomic testing; (iv) structured follow-up processes should be implemented for monitoring the clinical effectiveness of MTBs recommendations and (v) finally, the panel proposed quality indicators for operating MTBs, including turnaround times for cases discussion and the proportion of cases for which actionable recommendations and clinical trial enrolments were successfully implemented. Conclusions These ESMO’s POWG recommendations can serve as a guidance and help to define quality standards for MTBs to allow for harmonisation and to further expedite the integration of precision oncology into clinical practice.
This project was funded by the European Society for Medical Oncology (no grant number).
Article
Published version
English
Càncer - Tractament; Genòmica; Medicina personalitzada; Assistència sanitària - Control de qualitat; DISEASES::Neoplasms; Other subheadings::Other subheadings::/therapy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Precision Medicine; DISCIPLINES AND OCCUPATIONS::Natural Science Disciplines::Biological Science Disciplines::Biology::Computational Biology::Genomics; HEALTH CARE::Health Services Administration::Quality of Health Care::Quality Indicators, Health Care; ENFERMEDADES::neoplasias; Otros calificadores::Otros calificadores::/terapia; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::medicina de precisión; DISCIPLINAS Y OCUPACIONES::disciplinas de las ciencias naturales::disciplinas de las ciencias biológicas::biología::biología computacional::genómica; ATENCIÓN DE SALUD::administración de los servicios de salud::calidad de la atención sanitaria::indicadores de calidad en la asistencia sanitaria
Elsevier
Annals of Oncology;36(6)
https://doi.org/10.1016/j.annonc.2025.02.009
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
